Dr Lal Pathlabs Ltd vs Syngene International Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 24, 2026

Key Highlights

The Latest Trading Price of Dr Lal Pathlabs Ltd is ₹ 1845 as of 23 Oct 15:30 . The P/E Ratio of Dr Lal Pathlabs Ltd changed from 77.4 on March 2021 to 43.6 on March 2026 . This represents a CAGR of -9.12% over 6 yearsThe P/E Ratio of Syngene International Ltd changed from 53.7 on March 2021 to 49.7 on March 2026 . This represents a CAGR of -1.28% over 6 years The Market Cap of Dr Lal Pathlabs Ltd changed from ₹ 22565 crore on March 2021 to ₹ 22015 crore on March 2026 . This represents a CAGR of -0.41% over 6 yearsThe Market Cap of Syngene International Ltd changed from ₹ 21734 crore on March 2021 to ₹ 15724 crore on March 2026 . This represents a CAGR of -5.25% over 6 years The revenue of Dr Lal Pathlabs Ltd for the Jun '26 is ₹ 829.6 crore as compare to the Mar '26 revenue of ₹ 726.7 crore. This represent the growth of 14.16% The revenue of Syngene International Ltd for the Jun '26 is ₹ 761.3 crore as compare to the Mar '26 revenue of ₹ 1058 crore. This represent the decline of -28.09% The ebitda of Dr Lal Pathlabs Ltd for the Jun '26 is ₹ 279.4 crore as compare to the Mar '26 ebitda of ₹ 210.8 crore. This represent the growth of 32.54% The ebitda of Syngene International Ltd for the Jun '26 is ₹ 102.6 crore as compare to the Mar '26 ebitda of ₹ 319.6 crore. This represent the decline of -67.9% The net profit of Dr Lal Pathlabs Ltd changed from ₹ 107.8 crore to ₹ 170.5 crore over 9 quarters. This represents a CAGR of 22.60% The net profit of Syngene International Ltd changed from ₹ 75.7 crore to ₹ -9 crore over 9 quarters. This represents a CAGR of NaN% The Dividend Payout of Dr Lal Pathlabs Ltd changed from 59.51 % on March 2021 to 67.59 % on March 2026 . This represents a CAGR of 2.14% over 6 yearsThe Dividend Payout of Syngene International Ltd changed from 10.18 % on March 2022 to 16.52 % on March 2026 . This represents a CAGR of 10.17% over 5 years .

About Dr Lal Pathlabs Ltd

Dr. Lal PathLabs Limited was incorporated as a Private Limited Company with the name Dr. Lal PathLabs Private Limited', on February 14, 1995 at Delhi.
The business of the Partnership Firm, Central Clinical Laboratory was undertaken by the Company.
The Company converted into a Public Limited Company and name of the Company was changed to Dr. Lal PathLabs Limited' vide fresh Certificate of Incorporation granted by the RoC on August 19, 2015. Dr Lal PathLabs is among the most trusted diagnostic healthcare service provider in India, offering services through over 5000 diagnostic tests and related healthcare services through a nationwide network of medical laboratory centres.
Through its integrated, nationwide network, the Company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

About Syngene International Ltd

Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors.
Headquartered in India, the operations are driven by its highly qualified teams comprising 5641 scientists and its state-of-the-art facilities, spread over 2.5 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore.
The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers. Syngene International Limited was incorporated at Bangalore in 1993.
The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited.
The Company's health-related services extend across all major therapeutic areas and modalities.

FAQs for the comparison of Dr Lal Pathlabs Ltd and Syngene International Ltd

Which company has a larger market capitalization, Dr Lal Pathlabs Ltd or Syngene International Ltd?

Market cap of Dr Lal Pathlabs Ltd is 30,977 Cr while Market cap of Syngene International Ltd is 14,810 Cr

What are the key factors driving the stock performance of Dr Lal Pathlabs Ltd and Syngene International Ltd?

The stock performance of Dr Lal Pathlabs Ltd and Syngene International Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Lal Pathlabs Ltd and Syngene International Ltd?

As of October 24, 2026, the Dr Lal Pathlabs Ltd stock price is INR ₹1845.55. On the other hand, Syngene International Ltd stock price is INR ₹366.9.

How do dividend payouts of Dr Lal Pathlabs Ltd and Syngene International Ltd compare?

To compare the dividend payouts of Dr Lal Pathlabs Ltd and Syngene International Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.